CHENGDU, China, Jan. 16, 2026 /PRNewswire/ — From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK), was invited to attend the conference and delivered a keynote speech on the morning of January 15 (local time) and presented the Company’s latest achievements in drug R&D, commercialization, and globalization, and outlined its innovation strategy and future development plans.

Since initiating its innovation journey in 2012, Kelun-Biotech has rapidly emerged as a leader in China’s innovative drug field, building differentiated technology platforms and robust R&D pipelines. Leveraging its global leading OptiDC™ platform for antibody-drug conjugates (ADCs) and novel drug conjugates (DCs), the Company continuously advances the differentiated development of ADCs and novel DCs, forming a gradient portfolio for treating multiple tumor types. Currently, Kelun-Biotech has two ADC products on market: sacituzumab tirumotecan (sac-TMT, 佳泰莱^®) and trastuzumab botidotin (舒泰莱^®), covering breast cancer and lung cancer indications. Additionally, nine uniquely designed ADC and novel DC drugs—including cutting-edge directions such as bispecific ADC and radiopharmaceutical conjugate (RDC) are in clinical stage. For high-incidence tumor types in China, such as breast cancer, lung cancer, and gastrointestinal tumors, the Company has initiated nine pivotal studies, while multiple Phase II clinical studies targeting gynecological tumors are progressing steadily. Furthermore, Kelun-Biotech has also developed several non-DC candidates and expanded indications into non-oncology areas.

Over the past year, Kelun-Biotech has presented multiple research findings at international academic conferences and published in authoritative journals: three were selected for oral presentations at the American Society of Clinical Oncology (ASCO) annual meeting, and three were selected as Late-Breaking Abstracts (LBA) for oral presentations at the European Society for Medical Oncology (ESMO) Congress. Among these, the results of the OptiTROP-Lung04 study of sac-TMT for treating EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) after TKI therapy were presented at the Presidential Symposium session of ESMO and simultaneously published in The New England Journal of Medicine, highlighting its global academic and clinical value.

In terms of commercialization, Kelun-Biotech has formed a competitive initial product portfolio. Its core product, the TROP2-directed ADC sac-TMT, has been approved in China for three indications: second-line and above triple-negative breast cancer, second-line and third-line EGFR-mutated NSCLC. The HER2-directed ADC trastuzumab botidotin was approved last year for second-line and above HER2-positive breast cancer, becoming the first domestically developed HER2-directed ADC approved for this indication. Furthermore, the anti-EGFR monoclonal antibody Cetuximab N01 (达泰莱^®) for RAS wild-type colorectal cancer and the anti-PD-L1 monoclonal antibody tagitanlimab (科泰莱^®) for nasopharyngeal carcinoma have been launched. Another small-molecule RET inhibitor A400 is expected to be approved within the year, bringing the total number of commercialized products in China to five. Currently, three of the Company’s commercialized products, covering five indications, have been included in the National Reimbursement Drug List (NRDL), further benefiting a broad population of cancer patients.

While strengthening its presence in the domestic market, Kelun-Biotech is actively expanding overseas. It has established collaborations with MSD, Ellipses, Windward Bio and Crescent Biopharma to maximize the value of its pipeline value and corporate worth. Among these, MSD is evaluating 16 global Phase III clinical studies of sac-TMT.

The breakthroughs in both clinical development and commercialization are driven by the Company’s sustained investment in innovative R&D. With over a decade of accumulation in the ADC field, Kelun-Biotech’s proprietary OptiDC™ platform enables differentiated design of drug candidates, which combines specific targets or targeting mechanisms with the most suitable payload-linker strategy to balance efficacy and safety. Additionally, the company is adopting a “multi-pronged” innovation strategy to continuously enhance platform capabilities. By exploring novel targets, new payloads, and diverse conjugation technologies, it is expanding the application boundaries across both oncology and non-oncology fields.

Looking ahead, Kelun-Biotech will consolidate its foundations in R&D, technologies, platforms, and operations by executing five key development strategies. Concurrently, the Company will elevate its globalization strategy, enhancing its capabilities in product development, registration, and commercialization in ex-China market, advancing on its path to becoming a world-class biopharmaceutical company.

Please refer to the “Investor Relations-Investor Calendar” page of the company’s official website for the presentation materials. You can visit the website for further details.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

Source

SHANGHAI, Jan. 15, 2026 /PRNewswire/ — HOTELEX Shanghai 2026 will take place from 30^th March to 2^nd April 2026, offering global hospitality and foodservice suppliers a direct gateway to China and the wider Asian market. Building on the record-breaking success of the 2025 edition, the exhibition will return with expanded scale, stronger international buyer engagement, and enhanced commercial value. With over 3,500 exhibitors, 12,000 overseas buyers, and a fully integrated industry ecosystem, HOTELEX Shanghai 2026 provides a high-impact platform for sourcing, partnerships, and long-term market expansion.

HOTELEX Shanghai 2025 welcomed a record 284,581 professional visitors, including a 34.2% increase in international buyers. Exhibitors reported a 37% rise in qualified leads and a 23% increase in on-site transactions, demonstrating the exhibition’s effectiveness as a high-performance sourcing and business platform. Building on this success, the 34ᵗʰ edition in 2026 will offer expanded exhibition space, deeper international participation, and increased opportunities for global decision-makers, distributors, and strategic partners.

Covering 400,000 square meters, the exhibition will host more than 3,500 leading domestic and international suppliers across key sectors including Kitchen Equipment, Coffee & Tea, Catering Ingredients, Beverages, and Baking Supplies. This fully integrated ecosystem supports end-to-end sourcing, innovation, and cross-border collaboration.

HOTELEX’s competitive advantage lies in its comprehensive industry coverage. By integrating resources across hospitality, catering, cultural tourism, retail, logistics, and health sectors, the exhibition drives value-chain synergies and reflects the evolving structure of the modern hospitality economy. Its distinctive “tourism–catering–hotel joint exhibition” model offers a holistic showcase spanning food, accommodation, travel, shopping, and leisure.

Leveraging a shared pool of over 100,000 professional buyers from HOTELEX and FHC, exhibitors gain extended brand exposure through official digital platforms and global social media channels including LinkedIn, YouTube, Facebook, and TikTok, as well as partnerships with authoritative industry media. Booths are limited – reserve yours early to secure prime exhibition space and maximize business opportunities. Positioned as a strategic gateway, HOTELEX Shanghai 2026 empowers global companies to grow their presence in China and accelerate expansion across Asia’s hospitality and foodservice markets.

Pre-registration: https://www.hotelex.cn/en/shanghai

Contact Us：
Booth Inquiry:
Jason Jin
Tel: +86 21 3339 2197
Junyan.Jin@imsinoexpo.com

Media & Visitor Consulting:
Lizzy Chen
Tel: +86 21 3339 2566
Lizzy.chen@imsinoexpo.com

Source

HANOI, Vietnam, Jan. 15, 2026 /PRNewswire/ — As Vietnam’s tourism sector enters a post-pandemic restructuring phase, trends with the potential to generate long-term value are increasingly taking centre stage in the industry’s development strategies. Against this backdrop, The Insiders Forum – a deep-dive seminar series within the HOTLIST Travellive Editor’s Pick initiative organised by Travellive Media Group has been established as a professional dialogue platform to examine new growth drivers shaping Vietnam’s tourism industry within a broader regional context.

Within the 2025 theme “The Journey from Seed to Harvest”, The Insiders Forum highlights the principles of sustainable development, long-term vision, and values cultivated over time, reflecting priorities that are shaping the future of tourism.

The Insiders Forum Hanoi held on 7 January at Sheraton Hanoi West, attracted more than 300 participants including industry experts, business leaders, and senior representatives from across the tourism and hospitality sectors. The event featured prominent speakers such as Ms. Hildegard Anzenberger (General Manager, Capella Hanoi), Mr. Mario Mendis (General Manager, Fusion Resort & Villas Da Nang), Dr. Nguyen Ngoc Huy (Climate Change Research Expert) and other speakers. The presence of professional speakers with strong practical expertise and strategic perspectives underscored the forum’s professional credibility and the depth of its industry dialogue.

Discussions at The Insiders Forum Hanoi reflected the strong recovery momentum of Vietnam’s tourism sector, which is laying the groundwork for significant structural shifts. Tourism revenue in 2025 is estimated to exceed VND 1 quadrillion, representing an increase of approximately 19% compared to 2024 and marking the highest annual revenue level recorded to date.

The forum focused on high value-added segments, including luxury tourism, wellness and medical tourism, aviation connectivity, as well as the role of local identity and cultural heritage in shaping destination experiences. Panel discussions emphasised that Vietnam’s competitive advantage does not lie in low costs or mass-scale offerings, but rather in its ability to integrate natural landscapes, culture, service quality, and personalised experiences into differentiated tourism products.

Organised in both Hanoi and Ho Chi Minh City, The Insiders Forum goes beyond trend updates to position itself as a strategic dialogue platform, connecting industry professionals and fostering a more in-depth, sustainable approach to tourism development.

Following the Hanoi event, The Insiders Forum Ho Chi Minh City will take place on 19 January at JW Marriott Hotel & Suites Saigon. The forum will explore key factors shaping the industry’s next development phase, with in-depth discussions on destination marketing, MICE and the practical challenges of translating market potential into sustainable competitive advantages for Vietnam amid intensifying regional competition.

Through this seminar series, Travellive Media Group continues to affirm its role as a specialised industry media platform, one that not only reflects market developments, but also actively contributes to shaping industry thinking, standards, and long-term development pathways for Vietnam’s tourism sector.

Source

SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ — Yuyu Bio and Mervyn’s Petcare, pet-focused subsidiaries of Yuyu Pharma, have opened a new office on the UCLA campus, strengthening the company’s presence in the United States pet and animal health market.

The two companies are now based at Magnify, the startup incubator housed within the California NanoSystems Institute (CNSI) at UCLA. Magnify provides office space, meeting facilities, and access to a dynamic innovation ecosystem. The new office will serve as Yuyu Pharma’s North American base for pet-related ventures, enabling closer collaboration with customers, partners, and industry stakeholders.

Yuyu Pharma has identified animal health and pet care as a next-generation growth engine and is advancing this strategy through Yuyu Venture Studio (YVS), its investment and venture-building platform that operates independently from the company’s core pharmaceutical business. Through YVS, Yuyu Pharma incubates and invests in emerging companies focused on veterinary biologics, pet nutrition, and animal wellness.

At UCLA, Yuyu Venture Studio has spun off two subsidiaries. Yuyu Bio is a biotechnology company developing feline-specific biologics for chronic and underserved conditions, while Mervyn’s Petcare is a cat-only health supplement company focused on science-backed wellness products. In addition to these UCLA-based companies, Yuyu Venture Studio has made strategic investments across the animal health ecosystem, including VETmAb Biosciences in canine biologics, Dalan Animal Health in shrimp vaccines for sustainable aquaculture, DOG PPL, a community and wellness platform centered around dog parks.

“The animal health sector is emerging as a major global growth area, driven by advances in biopharmaceutical science and rising demand for high-quality companion animal care,” said Robert Wonsang Yu, CEO of Yuyu Pharma. “Through Yuyu Venture Studio, we are building a diversified portfolio of animal health businesses while maintaining strategic independence from our core pharmaceutical operations. Establishing a presence at UCLA allows us to accelerate innovation and scale globally.”

About Yuyu Pharma

Founded in 1941, Yuyu Pharma is a Korea-based healthcare company focused on pharmaceuticals, medical devices, and health supplements that improve quality of life. As part of its global growth strategy, the company invests in early-stage and high-growth innovators across biotechnology, sustainability, and animal health through Yuyu Venture Studio.

Source

SINGAPORE, Jan. 14, 2026 /PRNewswire/ — Kerry, a global leader in taste and nutrition, today unveiled its 2026 Global Taste Charts, providing the food and beverage industry with its most comprehensive and forward‑looking view of flavour evolution. Built on research from more than 1,200 scientists, 100 flavourists and extensive consumer studies across regions, the Charts offer manufacturers a data‑driven roadmap for fast‑moving flavour trends.

This year’s edition expands from six to eight categories: Refreshing Beverages; Alcohol & Alcohol‑Inspired Drinks; Tea, Coffee & Cocoa; Savoury Snacks; Sweet; Soups & Dressings; Meat & Meals; and Supplements, capturing the growing interplay between indulgence and wellness, global inspiration and local identity.

Flavour Trends Across Asia Pacific, Middle East & Africa (APMEA)

The Rise of “Swicy”
Sweet‑and‑spicy combinations are surging, especially among Gen Z. Southeast Asia sees spicy fruit drinks and chilli‑laced confectionery, while South Africa showcases sweet‑chilli sauces, hot honey snacks and spicy tomato crisps.

Nuanced Heat & Global‑Local Blends
Greater Africa embraces paprika‑driven blends in snacks, sauces and grilled meats. In Australia and New Zealand, fajita spice is emerging as a fast‑growing favourite in meal kits, marinated meats and savoury snacks.

Fruit‑Forward Refreshment:
Watermelon continues leading beverage innovation across Southeast Asia and Africa. Meanwhile, mandarin is the fastest‑growing citrus flavour in Australia and New Zealand, expanding into alcoholic, alcohol‑inspired, tea and coffee formats.

Tradition Reworked
Traditional flavours are being reimagined in modern applications, from nasi uduk cheesecake and avocado brownie ice cream in Southeast Asia, to date mustard, za’atar ice cream and camel milk pistachio iced coffee in the Middle East.

Micro Moments of Indulgence
Bite‑sized, convenient treats are growing across the Middle East and South Africa, from chilli‑lemon snacks and energy balls to mini puddings and ready‑to‑cook proteins.

Healing & Functional Flavours
China continues blending Eastern and Western wellness traditions, incorporating turmeric, astragalus, aged tangerine peel, spirulina and açai into beverages, dairy and snacks.

Maximalist & Botanical Profiles:
Rich, extra‑strong milk teas, intensified matcha and cocoa, and decadent chocolate‑forward launches are rising in China and the Middle East, alongside botanicals such as orange blossom, hibiscus, rooibos and elderflower in South Africa and Asia Pacific.

Turning Insight into Action

The 2026 Taste Charts are supported by KerryNow™, Kerry’s end‑to‑end digital platform that allows customers to instantly order samples, explore the flavour portfolio and receive application and regulatory support, empowering faster innovation from concept to launch.

“The 2026 Taste Charts reflect how consumers are eating and drinking today, seeking contrast, comfort, depth and meaning in flavour,” said Leigh Anne Vaughan, Vice President of Product Technologies, Kerry. “It brings together sensory science, cultural understanding and real consumption data to show where flavours are gaining momentum and how they’re being expressed locally. By connecting these insights with practical application support and rapid sampling through KerryNow™, we’re helping our customers move more confidently from idea to product and keep pace with how quickly tastes are changing.”

Source